
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 5, 2019

ARDELYX, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36485
(Commission
File Number)

26-1303944
(IRS Employer
Identification Number)

**34175 Ardenwood Blvd., Suite 200
Fremont, CA 94555**
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (510) 745-1700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$0.0001	ARDX	The Nasdaq Global Market

Item 8.01 Other Events.

On June 5, 2019, Ardelyx, Inc. (the “Company”) updated its progress and projections with respect to its ongoing clinical trials for its lead compound tenapanor, indicating that it currently expects to announce data in the third quarter of 2019 from its Phase 3 AMPLIFY clinical trial evaluating tenapanor as adjunctive therapy with phosphate binders for the treatment of hyperphosphatemia in end-stage renal disease, or ESRD, patients on dialysis. This update narrowed the Company’s previous projection that it expected to announce such data in the second half of 2019. The Company reiterated its previously announced projection that it expects to announce data in the fourth quarter of 2019 from its ongoing Phase 3 PHREEDOM clinical trial evaluating tenapanor as monotherapy for the treatment of hyperphosphatemia in ESRD patients on dialysis.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 5, 2019

ARDELYX, INC.

By: /s/ Mark Kaufmann

Mark Kaufmann

Chief Financial Officer
